Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 33,851 shares, a decrease of 97.4% from the September 15th total of 1,297,436 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 130,379 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Ratings Changes

Several research firms recently commented on SGIOY. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

Shares of OTCMKTS:SGIOY traded down $0.05 during mid-day trading on Friday, hitting $8.70. 131,152 shares of the company traded hands, compared to its average volume of 188,565. The firm’s 50 day simple moving average is $9.07 and its 200 day simple moving average is $9.33. The firm has a market cap of $14.81 billion, a P/E ratio of 8.70, a PEG ratio of 3.14 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. Shionogi & Co., Ltd. Unsponsored ADR has a 52-week low of $7.65 and a 52-week high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. On average, equities analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.